Question 1

Are the samples sourced from commercial vendors

Accepted Answer

Yes, we procure live tissue samples from commercial vendors who in turn source them from a variety of hospitals. We also use the NCI network hospitals to obtain tissues.

Question 2

Is clinical data associated with these samples available?

Accepted Answer

We do have some clinical data available including therapeutic history from de-identified patient samples.

Question 3

Are the tumoroids frozen, separated and then reused?

Accepted Answer

Yes, we biobank them for the purpose of repeatability. Additionally, We have demonstrated growth of up to five generations without issue.

Question 4

Are the PBMC’s cryopreserved as such; or, do you maintain them as T-cells?

Accepted Answer

The entirety of the PBMCs are stored without expansion in lot sizes sufficient for long-term, longitudinal and repeat studies.

Question 5

Do the PDTs change over time?

Accepted Answer

We see no changes up to 5 generations. We also do not typically exceed a 28-day study timeframes in our experiments to ensure there are no substantive changes.

Question 6

With regards to heterogeneity, how do you account for the uniqueness of the location from which the biopsy was obtained?

Accepted Answer

We cannot obtain complete tumors. We address Intratumoral heterogeneity by using multiple tumor models of the same type and many thousands of tumoroids within each study.

Question 7

Do you use tumor chunks/fragments, or create spheroids of a specific size where there is loss of the original tumor architecture for the recreation of a 3D structure?

Accepted Answer

Our technology uses mechanically apportioned tumor to create Patient Derived Tumoroids (PDT’s). We do not create tumoroids of a single size but of a variety of sizes from 50-500 μm3. We think of it as growth of the tumor ex-vivo while retaining the tumor architecture and microenvironment.

Question 8

What is the rationale for using mechanical separation over enzymatic digestion?

Accepted Answer

We do this to ensure the stromal cells and the source tumor-microenvironment (TME) from the patients remain intact.

Question 9

Are the tumor models tested using autologous PBMC’s?

Accepted Answer

The Spanios PDT’s use HLA matched allogeneic PBMCs. We do it this way to enable repeatability of each batch for future experiments. Depending on your study goals, we can procure matched live tumor and PBMCs from the same patient if requested.

Question 10

How do you activate your PBMCs and ensure proliferation?

Accepted Answer

We add CD-28 and IL-2 to ensure activation. We have demonstrated that B-cells and macrophages are present. Yes, they can proliferate but we don’t allow them to change the TME.

Question 11

How do you intend to utilize your Perfusion Model to capture the patient response for complex modalities?

Accepted Answer

We do this with our next generation dynamic PDTs platform COMPASS 3 which utilizes a blood substitute. Both our COMPASS 2 and COMPASS 3 platforms help to better stratify your patients.

Question 12

What is the benefit of the COMPASS 3 Perfusion Model? Is it primarily to investigate immune incorporation?

Accepted Answer

The COMPASS 3 Perfusion Model is a more physiologically relevant platform as it works with a blood substitute to test agents in the presence of an oxygenated microenvironment versus hypoxic conditions. This can be done with or without the immune system components being present.

Question 13

Does your platform have stroma and the immune components?

Accepted Answer

This is dependent on the version of the model systems. COMPASS 1 platform models have the epithelium and stroma; while COMPASS 2 has both stroma and immune components. The COMPASS 3 Platform can model both all of the aforementioned both with and without oxygen modulation.

Question 14

Are myeloids present in the models?

Accepted Answer

We have tested B cells, T cells and Macrophages so far. We are in the process of testing all pertinent immunophenotypes including NK cells and Dendritics.

Question 15

Regarding T-cell engagement, NK cells, can you find signs of engagement and signs of exhaustion?

Accepted Answer

We can demonstrate this by performing cytokine studies. For example, we can test CD-28, CD-169 interaction through cytokines. We also have done checkpoint inhibitor studies. In immune competent organoids, we test anti-PD1 and anti-CTLA4. We have tested these in multiple tumoroids per sample in several indications over 14 days with great success.

Question 16

How comparable are Spanios PDT results to clinical outcomes?

Accepted Answer

Previous studies have shown that 80-85% of what has worked intratumorally has also worked in the clinical setup. Spanios PDT’s are the most translatable model available.

Question 17

What is your broad framework of studies that you do?

Accepted Answer

Apart from efficacy studies we focus a lot on mechanistic and biomarkers studies, and other routine ways of helping in patient selection criteria for clinical studies.

Question 18

How many treatment arms are possible (average) per specimen (it was mentioned that 4 replicates are run per treatment arm)?

Accepted Answer

We do  not have a limit on the treatment arms as our PDTs are always banked thus we can build as many arms as required. We suggest an n=4. We also usually do not have a limit on the number of assays that can be performed.

Question 19

What testing readouts do you offer?

Accepted Answer

We provide details of tumor volume reduction and tumor number reduction, both bulk and scRNA-seq, immunofluorescence, immunophenotyping, apoptosis, proliferation and migration assays, cytokine arrays, tumor cell and non-tumor cell high content imaging, MOA studies, Escape-response assessments, FACS, deep proteomics and H&E staining. Additional assays available upon request. Fully customizable.

Question 20

For cell therapies, could cell migration/tumor infiltration be followed and quantified via a cell fluorescence label?

Accepted Answer

Yes, we have followed the PBMCs by labeling them so TIL infiltration can be followed using a fluorescent label. Cell migration data is usually done using phase contrast microscopy over time.

Data from COMPASS 2 in a Client’s IND Filing

Critical Data

Client Needed

Drug X, an immune enhancer Evaluate if Drug X turns cold tumors hot Determine how it turns a cold tumor hot

Evaluating the potential of an immune enhancer in turning a cold tumor hot

Utilized COMPASS 2 platform Showed that Drug X, over time, increased incorporation of *TILs.

*TIL: Tumor Infiltrating Lymphocytes **TNBC: Triple Negative Breast Cancer #PD1: Programmed cell death protein

The data was utilized to take Drug X to Phase 2 trials. The trials are currently underway.

Study was completed in less than 5 months The data was part of client’s IND filing package.

In the *TNBC PDTs, Drug X in combination with anti-PD1# could:

Effect of Drug X and anti-PD1# combination was:

Drive antigen presentation Augment cell killing

Additive Not synergistic

Study Conducted

Data Generated

Outcome

Action

Value

Study Design

Expertise

IND Filing Currently in Phase 2

•••

••

••

••

••

••

Bottom Line: We Add Value to Our Client’s Work

Target Client

Type of Data

Shorter Timeframe

Higher Take Rate

Highly Translatable Data

How it works: Data Flywheel

IND Readiness

Range of Service

CUMULATIVE INSIGHT

INPUT

OUTPUT

•••

•••

Contact Us

Drug X, an immune enhancer
Evaluate if Drug X turns cold tumors hot
Determine how it turns a cold tumor hot

Utilized COMPASS 2 platform
Showed that Drug X, over time, increased incorporation of *TILs.

*TIL: Tumor Infiltrating Lymphocytes
**TNBC: Triple Negative Breast Cancer
#PD1: Programmed cell death protein

The data was utilized to take Drug X to Phase 2 trials.
The trials are currently underway.

Drive antigen presentation
Augment cell killing

Additive
Not synergistic

IND Filing
Currently in Phase 2

•
•
•

•
•

•
•

•
•

•
•

•
•

•
•
•

•
•
•